Valero Port Arthur Refinery Explosion Prompts $1M Lawsuit Over Worker Safety Negligence 
Novo Nordisk Launches Once-Daily Wegovy Pill in U.S. at Competitive Pricing 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
SpaceX IPO Filing Expected This Week as Valuation Could Surpass $75 Billion 
Lynas Rare Earths Signs Vietnam Deal with LS Eco Energy to Boost Magnet Metal Production 
NAB Plans to Cut 170 Jobs While Expanding Offshore Operations 
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 
Merck's $6 Billion Bid for Terns Pharma Signals Bold Oncology Push 
Air Canada Express Crash at LaGuardia: Controller Distracted by Prior Emergency 
FDA Fast-Track Drug Reviews Delayed Over Safety and Efficacy Concerns 
TrumpRx.gov Highlights GLP-1 Drug Discounts but Offers Limited Savings for Most Americans 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Google's TurboQuant Algorithm Sends Memory Chip Stocks Tumbling 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
CDC Acting Director Urges Measles Vaccination as U.S. Cases Surge in 2026 
Novo Nordisk A/S has finalized a groundbreaking deal to address the rising demand for its weight-loss drug, Wegovy, and diabetes treatment, Ozempic. In a significant move, Novo's largest shareholder has acquired Catalent Inc., one of the world's leading drug-manufacturing companies, for a staggering $16.5 billion, including debt.
As per Reuters, this three-way arrangement will see the Danish pharmaceutical company pay $11 billion to obtain three of Catalent's manufacturing facilities, fortifying its supply chain and overcoming recent shortages of Wegovy and Ozempic.
Fierce Competition and the Emergence of Zepbound
Novo Nordisk races to enhance its supply chain but faces fierce competition from Eli Lilly & Co. Lilly's obesity shot, Zepbound, was recently approved and is expected to become the highest-selling drug in history.
Yahoo pointed out that patient trials have demonstrated greater weight loss results with Lilly's drug compared to anything Novo has developed thus far. With this in mind, Novo's strategic acquisition of Catalent aims to solidify its market position and fend off the intensifying rivalry.
Novo Nordisk's purchase of Catalent has garnered support from Elliott Investment Management, an activist investor with a stake in the US company. The agreement values Catalent at $63.50 per share in cash, reflecting a 17% premium to its Friday closing price. However, Catalent faced manufacturing issues in September 2021, affecting its production of COVID-19 vaccines for Moderna Inc. and one of Regeneron Inc.'s top-selling drugs.
Novo Nordisk's Strategic Move to Meet Surging Demand Boosts its Market Value
Shares of Novo Nordisk have been surging alongside the increasing demand for its obesity and diabetes drugs, reaching a record high. With a market value exceeding $520 billion, Novo is now Europe's largest publicly traded company. Meanwhile, Catalent's stock rose by up to 10% in New York as news of the deal emerged.
This monumental $16.5 billion agreement between Novo Nordisk and Catalent marks the largest deal ever for companies and their controlling shareholder, Novo Holdings A/S. Novo Holdings currently controls 77% of the voting rights in the Danish drugmaker, further solidifying its influence and position in the pharmaceutical industry.
Photo: Novo Nordisk Newsroom
